Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 9043
Country/Region: Uganda
Year: 2015
Main Partner: Henry M. Jackson Foundation for the Advancement of Military Medicine
Main Partner Program: NA
Organizational Type: Private Contractor
Funding Agency: USDOD
Total Funding: $8,351,507 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $1,393,607
Care: Orphans and Vulnerable Children (HKID) $542,158
Care: TB/HIV (HVTB) $838,530
Care: Pediatric Care and Support (PDCS) $459,623
Laboratory Infrastructure (HLAB) $100,000
Strategic Information (HVSI) $1,750,000
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $649,891
Sexual Prevention: Abstinence/Be Faithful (HVAB) $55,870
Testing: HIV Testing and Counseling (HVCT) $291,162
Sexual Prevention: Other Sexual Prevention (HVOP) $476,516
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $328,317
Treatment: Adult Treatment (HTXS) $1,303,755
Treatment: Pediatric Treatment (PDTX) $162,078
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2016 2,428
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2016 6,638
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 249
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 672
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 4,700
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 12,999
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 292
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 801
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 7,669
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 21,110
CARE_CURR Sum of Aggregated Age/Sex disaggregates 2016 7,669
CARE_CURR Sum of Aggregated Age/Sex disaggregates 2016 21,110
CARE_NEW Aggregated Age/sex: <15 Female 2016 157
CARE_NEW Aggregated Age/sex: <15 Male 2016 141
CARE_NEW Aggregated Age/sex: 15+ Female 2016 2,765
CARE_NEW Aggregated Age/sex: 15+ Male 2016 1,502
CARE_NEW Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 4,565
CARE_NEW Sum of Aggregated Age/sex disaggregates 2016 4,565
CARE_NEW Sum of Aggregated Age/sex disaggregates 2016 4,565
FN_THER Aggregated Age: <18 2016 207
FN_THER Aggregated Age: 18+ 2016 326
FN_THER Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period 2016 533
FN_THER Sum of Aggregated Age disaggregates 2016 533
GEND_GBV Number of people receiving post-GBV care 2016 2,809
GEND_NORM Number of people completing an intervention pertaining to gender norms, that meets minimum criteria 2016 2,394
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2016 3,577
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2016 6,488
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 2,698
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 4,895
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 27,330
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 49,480
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 19,694
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 35,668
HTS_TST By Test Result: Negative 2016 51,339
HTS_TST By Test Result: Negative 2016 93,208
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 53,299
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 96,531
HTS_TST Sum of Aggregated Age/Sex <15 2016 6,275
HTS_TST Sum of Aggregated Age/Sex <15 2016 11,383
HTS_TST Sum of Aggregated Age/Sex 15+ 2016 47,024
HTS_TST Sum of Aggregated Age/Sex 15+ 2016 85,148
HTS_TST Sum of Aggregated Age/Sex disaggregates 2016 53,299
HTS_TST Sum of Aggregated Age/Sex disaggregates 2016 96,531
HTS_TST Sum of Test Result disaggregates 2016 53,299
HTS_TST Sum of Test Result disaggregates 2016 96,531
HTS_TST_POS By Test Result: Positive 2016 1,960
HTS_TST_POS By Test Result: Positive 2016 3,323
LAB_ACC Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation 2016 1
LAB_CAP By clinical laboratories 2016 3
LAB_CAP By Point-of-care testing sites 2016 11
LAB_CAP Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2016 3
OVC_ACC Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services 2016 5,591
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2016 10,879
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 1,324
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 1,324
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 1,103
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 221
PMTCT_ARV Sum of New and Current disaggregates 2016 1,324
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2016 131
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2016 1,316
PMTCT_EID Sum of Infant Age disaggregates 2016 1,316
PMTCT_STAT By: Known positives at entry 2016 1,134
PMTCT_STAT By: Number of new positives identified 2016 190
PMTCT_STAT Number of new ANC and L&D clients 2016 15,102
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 14,174
PMTCT_STAT Sum of Positives Status disaggregates 2016 1,324
PP_PREV Age/sex: 10-14 Female 2016 2,825
PP_PREV Age/sex: 10-14 Female 2016 221
PP_PREV Age/sex: 10-14 Male 2016 2,155
PP_PREV Age/sex: 10-14 Male 2016 239
PP_PREV Age/sex: 15-19 Female 2016 5,118
PP_PREV Age/sex: 15-19 Female 2016 3,347
PP_PREV Age/sex: 15-19 Male 2016 4,948
PP_PREV Age/sex: 15-19 Male 2016 3,598
PP_PREV Age/sex: 20-24 Female 2016 7,550
PP_PREV Age/sex: 20-24 Female 2016 4,469
PP_PREV Age/sex: 20-24 Male 2016 6,068
PP_PREV Age/sex: 20-24 Male 2016 4,802
PP_PREV Age/sex: 25-49 Female 2016 10,899
PP_PREV Age/sex: 25-49 Female 2016 2,792
PP_PREV Age/sex: 25-49 Male 2016 9,359
PP_PREV Age/sex: 25-49 Male 2016 2,998
PP_PREV Age/sex: 50+ Female 2016 729
PP_PREV Age/sex: 50+ Female 2016 333
PP_PREV Age/sex: 50+ Male 2016 700
PP_PREV Age/sex: 50+ Male 2016 354
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2016 50,351
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2016 23,153
PP_PREV Sum of Age/Sex disaggregates 2016 50,351
PP_PREV Sum of Age/Sex disaggregates 2016 23,153
TB_ART Aggregated Age: <15 2016 11
TB_ART Aggregated Age: 15+ 2016 166
TB_ART Female 2016 115
TB_ART Known HIV-positive 2016 80
TB_ART Male 2016 62
TB_ART Sum of Aggregated Age disaggregates 2016 177
TB_ART Sum of Sex disaggregates 2016 177
TB_ART Sum of Test Status disaggregates 2016 80
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2016 177
TB_SCREEN Aggregated Age - USE WITH HQ PERMISSION ONLY: <15 2016 1,478
TB_SCREEN Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ 2016 19,632
TB_SCREEN Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 7,669
TB_SCREEN Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 21,110
TB_SCREEN Sex: Female 2016 13,772
TB_SCREEN Sex: Male 2016 7,338
TB_SCREEN Sum of Aggregated Age disaggregates 2016 21,110
TB_SCREEN Sum of Sex disaggregates 2016 21,110
TB_SCREEN The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period 2016 21,110
TX_CURR Aggregated Age/Sex: 15+ Female 2016 1,869
TX_CURR Aggregated Age/Sex: 15+ Female 2016 5,796
TX_CURR Aggregated Age/Sex: 15+ Male 2016 4,079
TX_CURR Aggregated Age/Sex: 15+ Male 2016 12,572
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 6,405
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 19,844
TX_CURR Sum of Aggregated Age/Sex 15+ 2016 5,948
TX_CURR Sum of Aggregated Age/Sex 15+ 2016 18,368
TX_CURR Sum of Aggregated Age/Sex disaggregates 2016 5,948
TX_CURR Sum of Aggregated Age/Sex disaggregates 2016 18,368
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2016 2,112
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2016 4,461
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2016 6,856
TX_NEW Sum of Aggregated Age/Sex disaggregates 2016 6,573
VMMC_AE Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs) 2016 42
VMMC_CIRC By circumcision technique: Device-based VMMC 2016 3
VMMC_CIRC By circumcision technique: Surgical VMMC 2016 12,889
VMMC_CIRC By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery 2016 3
VMMC_CIRC By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery 2016 12,889
VMMC_CIRC By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site 2016 3,738
VMMC_CIRC By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program) 2016 8,918
VMMC_CIRC By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site) 2016 233
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2016 12,889
Cross Cutting Budget Categories and Known Amounts Total: $4,232,115
Key Populations: Sex Workers $400,000
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Training of health workers and community outreach workers
Collection and use of strategic information on SWs and clients
Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Monitoring and evaluation of SW programs
Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Key Populations: MSM and TG $300,000
Training of health workers and community outreach workers
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Collection and use of strategic information
Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Monitoring and evaluation of MSM/TG programs
Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Water $10,000
Economic Strengthening $100,000
Food and Nutrition: Commodities $30,000
Food and Nutrition: Policy, Tools, and Service Delivery $50,000
Human Resources for Health $372,115
Construction $2,700,000
Motor Vehicles: Purchased $270,000